8-K: Calidi Biotherapeutics Issues Warrants and Convertible Note to Ingodwe Trust

Calidi Biotherapeutics has entered into a convertible promissory note agreement with Ingodwe Trust, issuing warrants and a convertible note for a $1 million loan.

Summary

• Calidi Biotherapeutics secured a $1 million loan from Ingodwe Trust through a convertible promissory note purchase agreement.
• The note carries a 12% simple interest rate per annum and matures on January 26, 2025.
• Ingodwe Trust has the option to convert the note's principal and accrued interest into company stock at a 10% discount to the 10-day VWAP prior to January 26, 2024.
• Upon conversion, Ingodwe Trust will also receive warrants to purchase shares equal to 50% of the converted shares at an exercise price of 120% of the conversion price.
• The warrant is exercisable until 2027.
• The agreement includes provisions for mandatory conversion of the note into equity securities if Calidi Biotherapeutics completes a public offering before the note's maturity.
• The warrant and shares issued upon exercise are subject to transfer restrictions and compliance with securities laws.

Sentiment

Score: 6

Explanation: The document outlines a standard financing agreement. While the loan provides necessary capital, the terms are not exceptionally favorable or unfavorable. The sentiment is neutral to slightly positive.

Positives

• The $1 million loan provides Calidi Biotherapeutics with working capital.
• The convertible note structure allows for potential equity upside for the lender.
• The warrant provides an additional opportunity for the lender to benefit from potential stock appreciation.
• The company has the option to prepay the loan without penalty.

Negatives

• The 12% interest rate on the loan could be considered high.
• The mandatory conversion clause could dilute existing shareholders if a public offering occurs.
• The warrant and shares issued upon exercise are subject to transfer restrictions.

Risks

• The company's ability to repay the loan or achieve a successful public offering is uncertain.
• The conversion of the note and exercise of warrants could dilute existing shareholders.
• The transfer restrictions on the securities could limit the lender's ability to liquidate their investment.

Future Outlook

The company intends to use the loan proceeds for working capital purposes. The note may convert into equity securities upon a public offering or at the lender's option. The company is also obligated to file a registration statement for the resale of the shares issued upon conversion.

Management Comments

• The company has not provided any direct quotes in this document.

Industry Context

This type of financing is common for biotech companies seeking to fund operations and research. The use of convertible notes and warrants is a typical method for attracting investors in the biotech sector, which often involves high risk and potential high reward.

Comparison to Industry Standards

• Convertible notes are a common financing tool for early-stage biotech companies, similar to companies like XOMA Corporation and Agenus Inc, which have used similar instruments to raise capital.
• The 12% interest rate is relatively high, reflecting the risk associated with investing in a pre-revenue biotech company. This is comparable to other high-risk biotech financings.
• The warrant coverage of 50% of the converted shares is within the typical range for such transactions, although the specific terms can vary widely based on the company's stage and market conditions.
• The conversion discount of 10% is a standard incentive for lenders to invest in convertible notes, similar to what is seen in other biotech financings.

Stakeholder Impact

• Shareholders may experience dilution if the note is converted into equity.
• The loan provides the company with capital to continue operations, which benefits employees and other stakeholders.
• The lender, Ingodwe Trust, benefits from the potential for equity upside and interest income.

Next Steps

• The company will use the loan proceeds for working capital.
• The company may need to file a registration statement for the resale of shares issued upon conversion.
• The lender may choose to convert the note into equity.

Key Dates

Keywords

convertible note, warrant, loan, equity financing, working capital, common stock, securities, biotherapeutics, investment